For OS, we found that low-expression GSN was an adverse factor affecting OS in patients with CESC, KIRC, SARC, and low-expression GSN was a protective variable for BLCA, LAML and LGG patients (p < 0.05; Figure 4A and Supplementary Figure S1A). Here, GSN is linked to bladder transitional cell carcinoma.